Natco Pharma Limited

BSE: 524816 NSE: NATCOPHARM
Natco Pharma Limited - agriculture in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24230TG1981PLC003201 Incorporated 19 September 1981 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: NATCOPHARM · BSE: 524816 Public Limited Company agriculture Fortune India 500 · #485 Nifty 500
Market Cap
₹15,869 Cr
NATCOPHARM · NSE
Share Price
₹820.20
+1.39% today
Revenue
₹4,078 Cr
FY 2025-26 · -7.9% YoY
EBITDA
₹1,436 Cr
Margin 35.2%
Net Profit
₹1,437 Cr
FY 2025-26 · -23.7% YoY
P/E (TTM)
13.8x
P/B 1.5x
ROE
16.3%
ROCE 17.0%
Debt / Equity
0.06
Interest cover 3.0x

About Natco Pharma Limited

Data last updated:

Natco Pharma Limited is a public limited company based in Hyderabad, Telangana, India. It operates in the fertilizers and soil enhancers segment of the agriculture sector. It was incorporated on 19 September 1981 and has been in existence for over 45 years.

Natco Pharma is ranked #485 on the Fortune India 500 (2025). It is part of the Nifty 500 and BSE 500 indices. Its director VC Nannapaneni is #513 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1981PLC003201. Its GSTIN is 36AAACN6927A1ZQ (Telangana). The company holds 32 GST registrations, of which 25 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 524816 and NSE: NATCOPHARM.

The company has an authorised share capital of ₹45 Cr and a paid-up capital of ₹35.82 Cr. It was formerly known as Natco Fine Pharmaceuticals Private Limited. It is led by directors including Venkaiah Chowdary Nannapaneni (Managing Director) and Potluri Prasad Sivaramakrishna (Whole-Time Director).

Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Natco House Road No.2 Banjara Hills, Hyderabad, Telangana, India – 500034.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹4,078.3 Cr, a decline of 7.9% compared to the previous year. For the same year it recorded a net profit of ₹1,436.58 Cr (net margin 35.2%) and EBITDA of ₹1,436.5 Cr (EBITDA margin 35.2%). The net worth stands at ₹9,221.1 Cr (up 21.2% YoY). Total assets are valued at ₹10,002 Cr (up 25.6% YoY).

The company has about 5,120 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Natco Pharma. As per MCA filings, the company has open charges of ₹1,120 Cr and satisfied charges of ₹1,277.71 Cr on record. Court records list 326 cases involving the company, including 159 filed by the company and 167 filed against it; 73 cases are pending. The company has 53 deals on record (43 market trades, 3 secondary share transfers, 3 funding rounds), with disclosed funding of ₹1,324.88 Cr; the latest was in November 2025. The company has 8 MSME Form 1 returns on record between 2019 and 2024, listing 258 overdue payments to 52 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website natcopharma.co.in.

Company details

CIN L24230TG1981PLC003201
Registration Number 003201
Incorporation Date 19 September 1981
ROC Hyderabad
Listing Status Listed - Listed on NSE (NATCOPHARM); Listed on BSE (524816)
Company Status Active
Compliance Status Active Compliant

CIN history

Natco Pharma has one previous CIN (Corporate Identification Number): L24230AP1981PLC003201. The current CIN is L24230TG1981PLC003201, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24230TG1981PLC003201Current
L24230AP1981PLC003201Previous
Key People
Venkaiah Chowdary Nannapaneni Managing Director Potluri Prasad Sivaramakrishna Whole-Time Director Lingarao Donthineni Whole-Time Director

Recognitions & Rankings of Natco Pharma

Fortune India 500 2025 edition
Rank#485
Total income
₹4,797 Cr
Profit
₹1,885 Cr
India's Most Valuable Companies 2024 edition · Source: Hurun India
Rank#223
Valuation
₹26,610 Cr
2023 #278 2022 #309 2021 #238
India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Natco Pharma Limited's registered office is in Hyderabad, Telangana. Its website is natcopharma.co.in. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    natcopharma.co.in
  • Social Media
  • Registered Address
    Natco House Road No.2 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Agriculture, Fertilizers & Soil Enhancers

To see the full contact details of Natco Pharma Limited, buy the company report.

Comprehensive company report
Natco Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Natco Pharma operates one associated brand: Natco Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Natco Pharma
APIs and finished dosage forms are developed and manufactured.natcopharma.co.in

Business activity

The main business activity of Natco Pharma is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Natco Pharma Limited, buy the company report.

Financials of Natco Pharma Limited

FY 2025-26 filings available

Natco Pharma Limited reported revenue of ₹4,078.3 Cr (down 7.9% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹4,078 Cr
-7.9% YoY
EBITDA
₹1,436 Cr
-34.6% YoY
Profit After Tax
₹1,437 Cr
-23.7% YoY
Net Worth
₹9,221 Cr
+21.2% YoY
Total Assets
₹10,002 Cr
+25.6% YoY
Total Debt
₹714 Cr
+155.5% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,0784,4303,9992,7071,9452,0521,915
Revenue growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
EBITDA1,4362,1961,751936264606583
EBITDA margin+35.2%+49.6%+43.8%+34.6%+13.6%+29.5%+30.4%
Profit before tax1,4912,2911,674862202580569
Net profit1,4371,8841,390701137417448
Net profit margin+35.2%+42.5%+34.8%+25.9%+7.1%+20.3%+23.4%
EPS (₹)79.25105.3377.5639.199.3224.1625.32
Balance sheet
Total assets10,0027,9626,2995,1284,7764,4924,192
Net worth9,2217,6075,8534,8744,2644,1223,774
Total debt714279371167416268316
Cash & bank1,5512,17695354620628466.00
Net working capital3,4034,2802,9732,1781,9801,9341,927
Cash flow
Cash from operations1,7681,6971,21284946.50299417
Cash from investing(1,987)(1,436)(1,026)(465)4.00(107)(175)
Cash from financing298(211)(247)(363)34.80(186)(251)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7357396471,3631,3291,2214751,371
Revenue growth (YoY)-44.7%-39.5%+36.3%-0.6%-2.5%---
Other income59.2077.8058.1010061.7066.3017663.80
EBITDA18612815957957154838.80804
EBITDA margin+25.4%+17.3%+24.5%+42.5%+43.0%+44.9%+8.2%+58.7%
Depreciation47.1050.4046.2052.4057.6098.3047.0045.80
Interest13.0010.909.5013.103.2010.204.404.10
Profit before tax186144161614572506164818
Tax63.40(89.20)20.7095.8091.6099.9031.30142
Net profit122233140518480406132676
EPS (₹)11.5314.968.4628.9426.8422.707.4337.81
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue3,5954,0943,5692,3511,7681,6541,790
Revenue growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
EBITDA1,3052,1441,637845213418578
EBITDA margin+36.3%+52.4%+45.9%+35.9%+12.1%+25.3%+32.3%
Profit before tax1,3642,2261,555771156392583
Net profit1,2821,7781,309622105285462
Net profit margin+35.7%+43.4%+36.7%+26.5%+6.0%+17.2%+25.8%
EPS (₹)71.55103.3772.9934.917.6216.9626.07
Balance sheet
Total assets9,3297,6796,0334,9504,6884,4484,274
Net worth8,5537,3345,5924,7024,1924,0913,870
Total debt709275366161400256314
Cash & bank1,1871,85786541210126354.10
Net working capital2,7883,8072,7261,9461,7881,8631,888
Cash flow
Cash from operations1,7761,6621,19678457.70184422
Cash from investing(2,078)(1,444)(960)(437)(92.50)(3.20)(165)
Cash from financing302(212)(237)(347)35.60(183)(261)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5976095291,2641,1931,1574081,293
Revenue growth (YoY)-50.0%-47.4%+29.7%-2.2%-3.6%---
Other income48.3072.9055.3093.3059.6062.1016851.40
Total expenses491516408712653596378502
EBITDA10692.4012055254056129.40791
EBITDA margin+17.8%+15.2%+22.7%+43.7%+45.3%+48.5%+7.2%+61.2%
Depreciation42.7045.6042.1048.1053.8093.7043.7042.20
Interest9.609.708.3011.702.608.803.403.00
Profit before tax102110125586543521150797
Tax27.40(99.60)18.3085.1078.8092.7025.40136

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 12 Nov 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue7357396471,3631,3291,2214751,371
Revenue growth (YoY)-44.7%-39.5%+36.3%-0.6%-2.5%---
Other income59.2077.8058.1010061.7066.3017663.80
EBITDA18612815957957154838.80804
EBITDA margin+25.4%+17.3%+24.5%+42.5%+43.0%+44.9%+8.2%+58.7%
Depreciation47.1050.4046.2052.4057.6098.3047.0045.80
Interest13.0010.909.5013.103.2010.204.404.10
Profit before tax186144161614572506164818
Tax63.40(89.20)20.7095.8091.6099.9031.30142
Net profit122233140518480406132676
EPS (₹)11.5314.968.4628.9426.8422.707.4337.81
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,0784,4303,9992,7071,9452,0521,915
Revenue growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
Other income29835412810599.00104107
Total expenses2,6422,2342,2471,7721,6811,4461,332
Employee cost687594525487445415375
EBITDA1,4362,1961,751936264606583
EBITDA margin+35.2%+49.6%+43.8%+34.6%+13.6%+29.5%+30.4%
Depreciation20723518716414311799.80
Interest36.7023.9019.2014.5017.7013.3021.50
Profit before tax1,4912,2911,674862202580569
Tax11940828514732.20137111
Net profit1,4371,8841,390701137417448
Net profit margin+35.2%+42.5%+34.8%+25.9%+7.1%+20.3%+23.4%
EPS (₹)79.25105.3377.5639.199.3224.1625.32
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital35.8035.8035.8036.5036.5036.5036.40
Reserves & surplus9,1857,5715,8174,8374,2274,0853,737
Shareholders' funds (net worth)9,2217,6075,8534,8744,2644,1223,774
Minority interest0.005.300.000.000.001.8011.20
Secured loans57318216774.90289128134
Unsecured loans14197.6020491.80126139182
Total debt714279371167416268316
Total liabilities10,0027,9626,2995,1284,7764,4924,192
Assets
Gross block4,2564,0163,6033,3753,1272,7022,149
Net block2,8032,6982,4912,4272,3122,0231,584
Capital work in progress29422513764.30130223518
Investments3,127474539392308304112
Inventories908766700743762798558
Sundry debtors8811,2471,189856621413551
Cash & bank balances1,5512,17695354620628466.00
Loans & advances1,1347617385506946981,122
Total current assets4,4744,9493,5802,6952,2832,1932,297
Total current liabilities1,071669607518303259370
Net working capital3,4034,2802,9732,1781,9801,9341,927
Total assets10,0027,9626,2995,1284,7764,4924,192
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash12070.4013211125.8019.8028.30
Net cash from operating activities1,7681,6971,21284946.50299417
Net cash from investing activities(1,987)(1,436)(1,026)(465)4.00(107)(175)
Net cash from financing activities298(211)(247)(363)34.80(186)(251)
Net change in cash78.9049.60(61.50)20.8085.306.00(8.50)
Closing cash1,5512,17695354620628466.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-7.9%+10.8%+47.7%+39.2%-5.2%+7.2%-
EBITDA growth-34.6%+25.4%+87.2%+255.1%-56.5%+4.1%-
PBT growth-34.9%+36.9%+94.2%+326.3%-65.1%+1.9%-31.0%
Net income growth-23.7%+35.5%+98.4%+410.1%-67.1%-7.0%-
Revenue CAGR (3Y)+14.6%+31.6%+24.9%+12.2%-2.4%-2.1%-1.8%
EBITDA CAGR (3Y)+15.4%+102.8%+42.4%+17.1%-30.8%-13.3%-5.2%
Profitability & leverage
Net income margin+33.6%+42.5%+34.7%+26.4%+8.7%+21.6%+23.9%
Return on capital employed+17.0%+32.5%+29.6%+17.7%+3.8%+13.7%+14.5%
Return on net worth+16.3%+28.0%+25.9%+15.7%+3.3%+11.2%+12.6%
Debt / equity0.060.050.050.060.080.070.10
Long-term debt / equity0.010.000.000.000.000.000.00
Interest cover2.981.221.231.8814.642.724.45
Efficiency & per share
Fixed asset turnover0.991.161.150.830.670.851.00
Inventory turnover4.876.045.543.602.493.033.52
Debtors turnover3.833.643.913.673.764.263.62
EPS (₹)79.25105.3377.5639.199.3224.1625.32
Dividend per share (₹)5.006.009.505.504.505.256.75
Book value per share (₹)515.15424.97326.99267.06233.62225.84207.34
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5976095291,2641,1931,1574081,293
Revenue growth (YoY)-50.0%-47.4%+29.7%-2.2%-3.6%---
Other income48.3072.9055.3093.3059.6062.1016851.40
Total expenses491516408712653596378502
EBITDA10692.4012055254056129.40791
EBITDA margin+17.8%+15.2%+22.7%+43.7%+45.3%+48.5%+7.2%+61.2%
Depreciation42.7045.6042.1048.1053.8093.7043.7042.20
Interest9.609.708.3011.702.608.803.403.00
Profit before tax102110125586543521150797
Tax27.40(99.60)18.3085.1078.8092.7025.40136
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue3,5954,0943,5692,3511,7681,6541,790
Revenue growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
Other income28132110585.5094.60101124
Total expenses2,2901,9501,9321,5061,5551,2361,212
Employee cost0.00515455426410380356
EBITDA1,3052,1441,637845213418578
EBITDA margin+36.3%+52.4%+45.9%+35.9%+12.1%+25.3%+32.3%
Depreciation19022017215113811598.10
Interest32.3019.6014.508.6013.3011.3020.60
Profit before tax1,3642,2261,555771156392583
Tax82.6037624913416.8082.70109
Net profit1,2821,7781,309622105285462
Net profit margin+35.7%+43.4%+36.7%+26.5%+6.0%+17.2%+25.8%
EPS (₹)71.55103.3772.9934.917.6216.9626.07
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital35.8035.8035.8036.5036.5036.5036.40
Reserves & surplus8,5177,2985,5564,6664,1554,0553,833
Shareholders' funds (net worth)8,5537,3345,5924,7024,1924,0913,870
Secured loans70627316774.90289128134
Unsecured loans2.901.5019986.20110128180
Total debt709275366161400256314
Total liabilities9,3297,6796,0334,9504,6884,4484,274
Assets
Gross block3,9943,7843,3603,1572,9782,6782,134
Net block2,6152,5172,2872,2342,1742,0061,574
Capital work in progress29322513462.80129223518
Investments3,265855742658550337191
Inventories724642597616698769524
Sundry debtors7601,1781,077793576400537
Cash & bank balances1,1871,85786541210126354.10
Loans & advances1,0767217085346746951,120
Total current assets3,7464,3983,2462,3552,0482,1262,235
Total current liabilities958591521409260263347
Net working capital2,7883,8072,7261,9461,7881,8631,888
Total assets9,3297,6796,0334,9504,6884,4484,274
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash11.205.506.905.905.107.9011.50
Net cash from operating activities1,7761,6621,19678457.70184422
Net cash from investing activities(2,078)(1,444)(960)(437)(92.50)(3.20)(165)
Net cash from financing activities302(212)(237)(347)35.60(183)(261)
Net change in cash0.305.70(1.40)1.000.80(2.80)(3.60)
Closing cash1,1871,85786541210126354.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-12.2%+14.7%+51.8%+33.0%+6.9%-7.6%-
EBITDA growth-39.2%+31.0%+93.8%+296.6%-49.0%-27.8%-
PBT growth-38.7%+43.1%+101.8%+394.4%-60.3%-32.7%-31.2%
Net income growth-27.9%+35.9%+110.3%+491.1%-63.1%-38.3%-
Revenue CAGR (3Y)+15.2%+32.3%+29.2%+9.5%-3.8%-7.5%-2.9%
EBITDA CAGR (3Y)+15.6%+115.9%+57.7%+13.5%-36.1%-23.4%-5.8%
Profitability & leverage
Net income margin+35.7%+45.2%+36.6%+27.1%+7.9%+18.7%+26.5%
Return on capital employed-+32.8%+28.6%+16.2%+2.8%+9.3%+14.6%
Return on net worth-+28.6%+25.4%+14.3%+2.5%+7.8%+12.8%
Debt / equity-0.050.050.060.080.070.09
Long-term debt / equity-0.000.000.000.000.000.00
Interest cover2.901.020.991.2417.833.744.29
Efficiency & per share
Fixed asset turnover-1.151.100.770.630.690.94
Inventory turnover-6.615.883.582.412.563.47
Debtors turnover-3.633.823.443.623.533.48
EPS (₹)71.55103.3772.9934.917.6216.9626.07
Dividend per share (₹)5.006.009.505.504.505.256.75
Book value per share (₹)0.00409.72312.42257.64229.69224.17212.61

To see the full year-wise statements and ratios of Natco Pharma Limited, buy the company report.

Board of directors of Natco Pharma Limited

Natco Pharma has 9 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Potluri Prasad Sivaramakrishna
Also directs: Natco Crop Health Sciences Limited
Whole-Time Director12 Nov 201412 Years 0 MonthsCurrent
Lingarao DonthineniWhole-Time Director11 Feb 201511 Years 9 MonthsCurrent
Venkaiah Chowdary Nannapaneni
Also directs: Natco Aqua Limited, NDL Infratech Private Limited, Natco Power Private Limited
Managing Director01 Apr 201511 Years 7 MonthsCurrent
Rajeev Nannapaneni
Also directs: Natco Aqua Limited, Natsoft Information Systems Private Limited, L V P Eye Innovations Foundation and 1 more
Whole-Time Director01 Jun 201214 Years 5 MonthsCurrent
Nitin Jain
Also directs: Amanta Healthcare Limited
Director12 Aug 20242 Years 3 MonthsCurrent
Suma Kantipudi
Also directs: Prasad Property Management Private Limited, HSRL Enterprises Private Limited, Melite Soft Technologies Private Limited and 3 more
Director12 Aug 20242 Years 3 MonthsCurrent
Showing 6 of 9 current directors. View all directors

Auditor

Natco Pharma Limited is audited by B S R and Co for the financial year 2025.

Auditor firmFinancial yearFirm registration number
B S R and CoFY 2025128510W

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 49.40%, foreign institutional investors hold 17.00%, domestic institutional investors hold 5.60% and retail and other public shareholders hold 28.00%.

Promoters: 49.40%DII (Domestic Institutional): 5.60%FII (Foreign Institutional): 17.00%Retail & Others: 28.00%
Sep 2026
QUARTER
49.40% Promoters
5.60% DII (Domestic Institutional)
17.00% FII (Foreign Institutional)
28.00% Retail & Others
Promoter holding - history
Now 49.40% · Sep 2026High 49.50% · Dec 2025Low 49.40% · Jun 2026
48%48.8%49.5%50.3%51%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 49.50%Mar 2026: 49.50%Jun 2026: 49.40%Sep 2026: 49.40%49.50%49.40%49.40%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters49.40%49.40%49.50%49.50%
Public50.60%50.60%50.50%50.50%

Charges & borrowings

Open charges
₹1,120 Cr
Satisfied charges
₹1,277.71 Cr
Breakdown by lending institutions
State Bank of India₹600.00 Cr
Others₹520.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
18 Jul 2025101136057State Bank of India₹600 CrOpen
08 Mar 201110271782Others₹520 CrOpen
18 Oct 2016100059941Others₹50 CrSatisfied
22 Jun 201510577202Citi Bank N.A.₹12.05 CrSatisfied
22 Dec 201410545846Citi Bank N.A.₹60 CrSatisfied

To see the full charge records of Natco Pharma Limited, buy the company report.

Total charge records: 58 View all charges

Deals & funding

Natco Pharma Limited has 53 deals on record (43 market trades, 3 secondary share transfers, 3 funding rounds), with disclosed funding of ₹1,324.88 Cr; the latest was in November 2025.

Total deals
53
Market trades
43
Secondary share transfers
3
Funding rounds
3
QIPs
2
Disclosed funding
₹1,324.88 Cr

Deals on record (5 of 53)

WhenDealAmountParties
Nov 2025Market trade₹108.54 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Apr 2025Market trade₹166.03 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Feb 2025Market trade₹86.58 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Sep 2022Acquisition₹15.73 CrBuyer: Odon Lifesciences Private Limited
Seller: Natco Pharma Limited
Feb 2012Market trade₹5.56 CrBuyer: Pasha Finance Private Limited
Seller: R K Chari Stock Broking Private Limited

To see the full deal history of Natco Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Natco Pharma Limited was last rated by Icra on 22 Mar 2020.

Rating agencyRated onRating
Icra22 Mar 2020

To see the full credit ratings and regulatory alerts of Natco Pharma Limited, buy the company report.

MSME payment delays

Natco Pharma Limited has 8 MSME Form 1 returns on record between 2019 and 2024, listing 258 overdue payments to 52 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 52)

SupplierAmount dueDue sinceReported on
Beko Technologies India Private Limited
Equitron Medica Private Limited
Ferron Equipments Private Limited
Protech - Progressive Technologies
an individual supplier

To see the full MSME payment records of Natco Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Employees & EPFO

Natco Pharma Limited has a workforce of 5,120 employees on its EPFO records as of May 2026, across 5 active EPFO establishments.

Employee count
5,120
Active EPFO establishments
5
Employee growth
2.7%

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2026-275,120
FY 2025-26
FY 2024-25
FY 2023-24
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Natco Pharma Limited, buy the company report.

GST

Natco Pharma has 32 GST registrations: 25 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
32
Active
25
Cancelled / inactive
7
GSTINStateStatusRegistered on
36AAACN6927A1ZQTelanganaActive01 Jul 2017
36AAACN6927A2ZPTelanganaActive01 Jan 2018
36AAACN6927A3ZOTelanganaActive17 Oct 2019
05AAACN6927A1ZVUttarakhandActive01 Jul 2017

To see the full GST registrations and return filing status of Natco Pharma Limited, buy the company report.

Recent activity

Natco Pharma Limited has 45 board changes on record since 1989: 27 appointments and 18 cessations. The latest: Ganapati Bhat Pavan ceased to be Whole-Time Director on 13 Feb 2025.

Filing
Natco Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
AGM
Natco Pharma Limited last Annual general meeting of members was held on 25 Sep 2025 as per latest MCA records.
Charges
A charge with State Bank Of India amounted to Rs. 600.00 Cr with Charge ID 101136057 was registered on 18 Jul 2025.
Ceased
Ganapati Bhat Pavan ceased to be Whole-Time Director.
Ceased
Leela Digumarti ceased to be Director.
Ceased
Venkateswara Rao Thallapaka ceased to be Director.
Appointed
Lakshminarayana Bolisetty was appointed as Director.
Appointed
Nitin Jain was appointed as Director.
Appointed
Suma Kantipudi was appointed as Director.
Ceased
Umamaheshwarrao Naidu Madireddi ceased to be Director.
Appointed
Agnihotra Dakshina Murty Chavali was appointed as Director.
Ceased
Govinda Prasad Dasu ceased to be Director.

184 earlier events are in the company report.

News

Natco Pharma Limited: Launches Carboplatin Injection, A Generic Version Of Paraplatin® In The U.S. To Tackle Critical Shortage; Expected Sales Of $27.8 Million
19 Oct 2026 · Exchange Update
NATCO Pharma: Gets Approval For ₹1,279.36 Crore Rights Issue; Will Issue 1,70,58,082 Shares At ₹750 Each
25 Sep 2026 · Exchange Update

Frequently asked questions

Natco Pharma is an active public limited company based in Hyderabad, Telangana, India. The company works in fertilizers and soil enhancers, within the agriculture industry. It was incorporated on 19 September 1981 (45+ years old) and is registered under CIN L24230TG1981PLC003201. Listed on BSE: 524816 and NSE: NATCOPHARM.

Natco Pharma reported revenue of ₹4,078.3 Cr for FY 2025-26 (down 7.9% YoY) based on consolidated financials.

Natco Pharma has 9 current directors:

The latest financial statements of Natco Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.

The GSTIN of Natco Pharma is 36AAACN6927A1ZQ, registered in Telangana. The company has 32 GST registrations in all, of which 25 are active and 7 are cancelled or inactive. Other active GSTINs include 36AAACN6927A2ZP (Telangana), 36AAACN6927A3ZO (Telangana), 05AAACN6927A1ZV (Uttarakhand).

The CIN (Corporate Identification Number) of Natco Pharma is L24230TG1981PLC003201. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Natco Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 524816) and NSE (symbol: NATCOPHARM).

Natco Pharma has 326 court cases on record: 159 filed by the company and 167 filed against it. 73 are pending. Most are in the high courts.

Natco Pharma was incorporated on 19 September 1981, making it 45+ years old. It is registered with the Registrar of Companies, Hyderabad.

Natco Pharma has 53 deals on record (43 market trades, 3 secondary share transfers, 3 funding rounds), with disclosed funding of ₹1,324.88 Cr; the latest was in November 2025.

Ganapati Bhat Pavan ceased to be Whole-Time Director on 13 Feb 2025. Leela Digumarti ceased to be Director on 21 Sep 2024. Venkateswara Rao Thallapaka ceased to be Director on 24 Aug 2024. Natco Pharma has 45 board changes on record in total.